Neurology

Mitra Habibi, PharmD, a clinical pharmacist at the University of Illinois Hospital and Health Sciences System, discusses challenges for specialty pharmacy in the management of patients with multiple sclerosis.

Role of specialty pharmacies in treatment of multiple sclerosis discussed during annual Armada summit.

Opexa Therapeutics is initiating a phase IIb trial of a novel therapy that targets T-cells in patients with secondary progressive multiple sclerosis.

The cooperative meeting of CMSC and ACTRIMS in Dallas platforms latest treatment, research and resources for MS health care professionals.

Patients taking Rebif (interferon beta-1a) may ask specialty pharmacists about recent reports of an increased risk of malignant hypertension with this specific formulation of interferon beta-1a.

Researchers in the United Kingdom have shown a reduction in the rate of brain atrophy progression with use of 80-mg simvastatin daily in patients with secondary-progressive multiple sclerosis over a 2-year period.

Integrated clinical and specialty pharmacy practice model includes an interdisciplinary team of physicians, nurses, and pharmacists.

Suzanne Tschida, PharmD, BCPS, vice president of specialty benefit and outcomes strategy at OptumRx, talks about how specialty medications are better suited for distribution through a specialty pharmacy over a retail location.

Although attention-deficit/hyperactivity disorder is a long-term condition, it can be managed with proper treatment.

Although attention-deficit/hyperactivity disorder is a long-term condition, it can be managed with proper treatment.

Genetics, the environment, and hormones may play a role in lupus.

Genetics, the environment, and hormones may play a role in lupus.

Our round-up of the latest Rx products.

Symptomatic and disease-modifying treatment options for multiple sclerosis.

Insomnia is one of the most prevalent patient complaints, ranking third after headaches and the common cold.

Patients require careful assessment before OTC analgesics for migraines can be recommended.

Cutaneous reactions occurred in most participants in a Netherlands-based multiple sclerosis therapy study, lowering dermatologic-specific quality-of-life scores.

MitoQ, an antioxidant drug under development by Antipodean Pharmaceuticals Inc, may have potential in treating multiple sclerosis in addition to other neurologic diseases.

Receptos is set to start phase III trials of a sphingosine-1–phosphate-1–receptor modulator codenamed RPC1063. Trial investigators are recruiting participants.

Amid conflicting evidence, Swedish researchers have found an association between multiple sclerosis (MS) and alcohol consumption, but the benefits of regular moderate alcohol intake in reducing the risk of MS may be attenuated by smoking.

The controversial chronic cerebrospinal venous insufficiency theory states that constricted vasculature is part of the pathophysiology of multiple sclerosis. A recent trial shows that the theory may be a scientific dead end.